Genscript Biotech Corporation
GNNSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $594,486 | $839,529 | $625,698 | $511,062 |
| % Growth | -29.2% | 34.2% | 22.4% | – |
| Cost of Goods Sold | $322,361 | $429,976 | $321,615 | $207,578 |
| Gross Profit | $272,125 | $409,553 | $304,083 | $282,518 |
| % Margin | 45.8% | 48.8% | 48.6% | 55.3% |
| R&D Expenses | $53,789 | $433,840 | $390,096 | $358,401 |
| G&A Expenses | $114,375 | $213,441 | $182,462 | $134,508 |
| SG&A Expenses | $202,496 | $387,739 | $350,811 | $302,477 |
| Sales & Mktg Exp. | $88,121 | $80,140 | $168,349 | $167,969 |
| Other Operating Expenses | $6,558 | $3,765 | $1,152 | -$9,148 |
| Operating Expenses | $262,843 | $825,344 | $742,059 | $651,730 |
| Operating Income | $9,282 | -$415,791 | -$436,038 | -$368,314 |
| % Margin | 1.6% | -49.5% | -69.7% | -72.1% |
| Other Income/Exp. Net | -$180,079 | $142,691 | -$3,934 | -$149,049 |
| Pre-Tax Income | -$170,797 | -$350,979 | -$431,690 | -$517,363 |
| Tax Expense | $2,977 | $4,142 | -$3,719 | $964 |
| Net Income | $2,961,877 | -$95,477 | -$226,851 | -$358,712 |
| % Margin | 498.2% | -11.4% | -36.3% | -70.2% |
| EPS | 1.4 | -0.045 | -0.11 | -0.18 |
| % Growth | 3,190.5% | 58.8% | 38.9% | – |
| EPS Diluted | 1.36 | -0.045 | -0.11 | -0.18 |
| Weighted Avg Shares Out | 2,121,285 | 2,107,707 | 2,097,135 | 2,030,598 |
| Weighted Avg Shares Out Dil | 2,178,302 | 2,109,365 | 2,097,135 | 2,030,598 |
| Supplemental Information | – | – | – | – |
| Interest Income | $28,894 | $73,186 | $13,218 | $2,785 |
| Interest Expense | $8,032 | $27,510 | $13,269 | $2,378 |
| Depreciation & Amortization | $60,754 | $74,119 | $64,311 | $47,508 |
| EBITDA | $70,036 | -$248,720 | -$355,079 | -$465,783 |
| % Margin | 11.8% | -29.6% | -56.7% | -91.1% |